Search
Tilactase
go.drugbank.com/drugs/DB13761ApprovedInvestigational[A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338]
Chymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. It is currently discontinued.[L2487] … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.
Neostigmine
go.drugbank.com/drugs/DB01400ApprovedInvestigationalVet approvedA cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Amsacrine
go.drugbank.com/drugs/DB00276ApprovedInvestigationalWithdrawnIt produces consistent but acceptable myelosuppression and cardiotoxic effects. … It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors.
Cedazuridine
go.drugbank.com/drugs/DB15694ApprovedInvestigational[A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by … [A215127, L14897] Although effective, these compounds are rapidly metabolized by cytidine deaminase (CDA) prior to reaching systemic circulation when administered orally, necessitating intramuscular or
Quercus alba pollen
go.drugbank.com/drugs/DB10376ApprovedQuercus alba pollen, or oak white pollen, is a non-standardized allergen extract used for the diagnosis and treatment of allergic disease to grass pollen. It can be subcutaneously administered to initiate an immune response in case of an...
Mixtures: 5-oak Mix, Blackjack/bur/post/red/white PollenManidipine
go.drugbank.com/drugs/DB09238ApprovedInvestigationalWithdrawnManidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.
Mixtures: VIVACE 30/10MG TABLETTEN, VIVACE 30/10MG TABLETTENProducts: MANYPER 10MG, MANYPER 20MGFamtozinameran
go.drugbank.com/drugs/DB17088ApprovedInvestigational[L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5.[L43907,L43912]
Ancrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnCurrently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S. … FDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood
Protein C
go.drugbank.com/drugs/DB11312ApprovedInvestigationalIt is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). … APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot